Repository logo
 
Publication

Conjugation of human topoisomerase 2A with small ubiquitin-like modifiers 2/3 in response to topoisomerase inhibitors: cell cycle stage and chromosome domain specificity

2008-04-01Journal article Open access
Simple item page
dc.contributor.authorAgostinho, Martapor
dc.contributor.authorSantos, Verapor
dc.contributor.authorFerreira, Fernandopor
dc.contributor.authorCardoso, Joana
dc.contributor.authorCosta, Rafael
dc.contributor.authorPinheiro, Inês
dc.contributor.authorRino, José
dc.contributor.authorJaffray, Ellis
dc.contributor.authorHay, Ronald
dc.contributor.authorFerreira, João
dc.date.accessioned2008-12-04T17:07:10Z
dc.date.available2008-12-04T17:07:10Z
dc.date.issued2008-04-01
dc.description.abstractType 2 topoisomerases, in particular the A isoform in human cells, play a key role in cohesion and sister chromatid separation during mitosis. These enzymes are thus vital for cycling cells and are obvious targets in cancer chemotherapy. Evidence obtained in yeast and Xenopus model systems indicates that conjugation of topoisomerase 2 with small ubiquitin-like modifier (SUMO) proteins is required for its mitotic functions. Here, we provide biochemical and cytologic evidence that topoisomerase 2A is conjugated to SUMO-2/3 during interphase and mitosis in response to topoisomerase 2 inhibitors and ‘‘poisons’’ (ICRF-187, etoposide, doxorubicin) that stabilize catalytic intermediates (cleavage complexes, closed clamp forms) of the enzyme onto target DNA. During mitosis, SUMO- 2/3–modified forms of topoisomerase 2A localize to centromeres and chromosome cores/axes. However, centromeres are unresponsive to inhibitors during interphase. Furthermore, formation of topoisomerase 2A–SUMO-2/3 conjugates within mitotic chromosomes strongly correlates with incomplete chromatid decatenation and decreases progressively as cells approach the metaphase-anaphase transition. We also found that the PIASy protein, an E3 ligase for SUMO proteins, colocalizes with SUMO-2/3 at the mitotic chromosomal cores/ axes and is necessary for both formation of SUMO-2/3 conjugates and proper chromatid segregation. We suggest that the efficacy of topoisomerase inhibitors to arrest cells traversing mitosis may relate to their targeting of topoisomerase 2A– SUMO-2/3 conjugates that concentrate at mitotic chromosome axes and are directly involved in chromatid arm separation. [Cancer Res 2008;68(7):2409–18]en
dc.identifier.urihttp://hdl.handle.net/10400.5/234
dc.language.isoengen
dc.publisherAmerican Association for Cancer Researchen
dc.relation.ispartofseriesVol. 68, n.7, p. 2409-2418
dc.subjectCanceren
dc.subjectTopoisomerase IIαen
dc.subjectSUMOen
dc.subjectCell cycleen
dc.titleConjugation of human topoisomerase 2A with small ubiquitin-like modifiers 2/3 in response to topoisomerase inhibitors: cell cycle stage and chromosome domain specificityen
dc.typejournal article
dspace.entity.typePublication
rcaap.rightsopenAccessen
rcaap.typearticleen

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Artigo_Conjugation of Human Topoisomerase 2A with Small Ubiquitin-like Modifiers 23 in Response to Topoisomerase Inhibitors Cell Cycle Stage and Chromosome Domain Specificity.pdf
Size:
776.44 KB
Format:
Adobe Portable Document Format
Description:
Artigo
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.81 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

DMF - Artigos de revista